EDC, eCOA, eConsent, and real-world evidence in one platform. Run your oncology, rare disease, cardiovascular, and CNS studies without integration overhead.
Select your therapeutic area to see how Castor handles the specific study designs, regulatory requirements, and patient populations unique to your programme.
Unified EDC and eCOA for adaptive, basket, and multi-cohort trials. Capture QoL endpoints with up to 95%+ patient compliance and minimal site burden.
Reach dispersed patient populations with native eConsent, decentralized clinical trials tools, and ePRO designed for complex small-N studies, including a 19,000+ subject genetics and rare disease registry with 119+ months of continuous data.
Capture daily ePRO and wearable data for GLP-1 and metabolic trials. No separate eCOA vendor required, with high daily ePRO compliance from a consumer-grade BYOD patient app.
Handle large Phase III and outcomes trials with unified EDC and RWE data collection across global multi-site studies. Castor Catalyst’s AI extraction layer turns uploaded site source documents (PDFs, EHR exports, and paper worksheets) into regulator-grade eCRF data, with human review, reducing data entry costs by up to 80%. Based on Castor’s analysis of 12 comparative Catalyst studies (2023 to 2024): manual chart transcription averaged about 39 minutes and $48.75 per chart, versus about 6 minutes and $9.75 per chart with Catalyst.
Deploy in days, not months. Trusted by global health organizations to power large-scale studies, including the global WHO Solidarity trial.
Capture validated cognitive and functional assessments natively in the EDC. No integration overhead, with a consumer-grade patient app.
Whatever the indication, the platform foundation is the same: unified, fast, and built for regulated environments.
Our electronic data capture system and eCOA run on the same database. Whether you’re capturing CTCAE toxicity grades in an oncology trial or running cognitive assessments in a CNS study, real-time data flows without reconciliation delays, sync failures, or a second vendor relationship. One login. One support channel. One source of truth.
Castor scopes each study build with managed Professional Services. Low-to-medium complexity studies typically move from kickoff (KOM) to user acceptance testing (UAT) in 4 to 8 weeks, and high-complexity studies in 8 to 12 weeks. For biotech teams racing a Phase I oncology IND or an orphan drug program, a scoped, managed build keeps the study on schedule.
21 CFR Part 11, ICH E6(R3) GCP, GDPR, and HIPAA compliance built in across all study types and TAs. From FDA oncology guidance to EMA rare disease regulations to CNS-specific endpoint standards, no separate implementation project is required when you add a new indication.
Castor’s eCOA solutions include a consumer-grade BYOD app in 15 to 20 languages delivering high ePRO compliance. Designed equally well for oncology patients reporting daily toxicity, elderly cardiovascular cohorts, rare disease paediatric populations, and CNS patients managing cognitive burden.
Recognized as a Major Contender in Everest Group’s Life Sciences eCOA Products PEAK Matrix® Assessment 2025.
Rated strongly for customer loyalty in ISR’s 2025 eCOA/ePRO Benchmarking.
Castor is a unified clinical trial platform supporting oncology, rare disease, cardiovascular, CNS and neurology, obesity and metabolic disease, and infectious disease studies on a single EDC and eCOA system. The platform has supported more than 18,000 studies across 160+ countries. Castor scopes each study build with managed Professional Services: low-to-medium complexity studies typically move from kickoff (KOM) to user acceptance testing (UAT) in 4 to 8 weeks, and high-complexity studies in 8 to 12 weeks. In the Oncobiomix oncology study, ePRO compliance reached up to 95%+, with a consumer-grade BYOD patient app available in 15 to 20 languages.
EDC and eCOA share a single source of truth, so data flows in real time across all six therapeutic areas without reconciliation delays or a second vendor.
Every study runs under 21 CFR Part 11, ICH E6(R3) GCP, GDPR, and HIPAA, with no separate implementation project required for each indication.
Studies run in 160+ countries with a patient app in 15 to 20 languages, so a single deployment covers single-region and global programmes across every supported indication.
Yes. Castor supports clinical trials across six therapeutic areas including oncology, rare disease, obesity and metabolic disease, cardiovascular, infectious disease, and CNS and neurology. Over 18,000 studies have run on Castor across 160+ countries on a single unified EDC and eCOA platform. Each therapeutic area has dedicated features for the specific study designs, regulatory requirements, and patient populations that clinical teams in that indication face.
In the Oncobiomix oncology study, ePRO compliance reached up to 95%+. The patient app supports 15 to 20 languages and is available as a BYOD consumer-grade app, reducing the compliance burden for patients across oncology, rare disease, and metabolic disease studies.
90% of Castor studies launch in under 4 weeks from signed contract to first patient in. Castor ranks in the top 5% of EDC vendors for shortest build time according to ISR 2023 benchmarks. This applies consistently across all six therapeutic areas Castor supports. Teams running biotech clinical trials and academic sponsors handling time-sensitive studies can expect the same build timeline regardless of indication.
Castor unifies EDC and eCOA on a single database, eliminating the integration layer that most vendors require between separate clinical and patient-reported outcome systems. This native architecture delivers real-time data capture across all therapeutic areas with no reconciliation delays and one source of truth for the entire study. Teams running oncology QoL endpoints, rare disease paediatric eConsent, or CNS cognitive assessments all work within the same platform without adding a separate vendor, API layer, or support contract.
Yes. Every study on Castor runs under 21 CFR Part 11, ICH E6(R3) GCP, GDPR, and HIPAA compliance, and that framework applies the same way across all six therapeutic areas. Compliance is built into the platform, so teams do not run a separate validation or implementation project for each indication. AI-assisted data extraction is always reviewed and confirmed by your team before data enters the record, which keeps the audit trail intact for regulatory submission.
Yes. Castor combines EDC, eCOA, eConsent, and real-world evidence in one platform, which supports decentralized, hybrid, and site-based designs across all six therapeutic areas. Studies run in 160+ countries with a BYOD patient app in 15 to 20 languages, local data hosting in Australia for APAC programmes, and native WeChat eCOA for sponsors running trials in China. Global rare disease and infectious disease programmes use the same unified platform as single-region oncology or cardiovascular studies.